- Trial phase
- Phase 1
- Time to market
- MGD024 is in Phase 1 testing with no disclosed timeline for Phase 2 or registrational studies. Approval, if successful, is likely several years away (5+ years under typical development timelines).
- Why 3/10
- MGD024 is an early Phase 1 program with no scheduled near-term binary catalyst. The company's next hard catalyst is MGC026 data mid-2027, not MGD024. MGD024 is one of several pipeline assets at MacroGenics and not the lead program. Per the rubric, an early-stage drug with no pending regulatory decision and no dated catalyst within ~12 months scores a 3.
MGD024 has no near-term binary catalyst, so it is unlikely to drive a significant stock move in the next 12 months on its own. Investors should watch for any Phase 1 data readout or Gilead option exercise on MGD024 specifically, but the company's near-term value inflection points are tied to MGC026 (data mid-2027) and lorigerlimab enrollment progress. MacroGenics' cash runway through 2028 reduces dilution risk but does not eliminate it.
Price Chart
Executive Summary
MGD024 is an investigational CD123xCD3 bispecific T-cell engager being developed by MacroGenics (MGNX) in collaboration with Gilead Sciences under a 2022 deal worth up to $1.76 billion in milestones. It is in Phase 1 testing for blood cancers. The program is early-stage and represents one of several pipeline assets at MacroGenics, which is currently prioritizing its B7-H3 ADC MGC026. No specific MGD024 data or near-term catalyst has been disclosed, and the stock's value is driven more by other pipeline programs and the company's cash position ($288M as of Q3 2026).
How It Works
MGD024 is a bispecific antibody built on MacroGenics' DART platform. It has two arms: one grabs CD123 (a protein found on the surface of certain blood cancer cells like leukemia) and the other grabs CD3 (a protein on immune T-cells). By binding both at once, it forces the immune system's T-cells to attack and kill the CD123-positive cancer cells. This is called a T-cell engager approach.
Trial Status
MGD024 is being studied in a Phase 1, first-in-human clinical trial for blood cancers (CD123-positive hematologic malignancies such as acute myeloid leukemia). The trial was noted as ongoing as of late 2025. MacroGenics' most recent corporate presentation (November 2026) still lists MGD024 in its pipeline, but the company has not disclosed specific enrollment updates or interim data for this program in recent quarters.
The Two-Sided Case
Upcoming Catalysts
- No specific near-term catalyst for MGD024 has been disclosed. The next company-wide pipeline catalyst is MGC026 data update expected mid-2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MACROGENICS INC 8-K MGNX ·Originating report